[Prevention and treatment of diabetic neuropathy].
Uesaka
Yoshikazu
Y
Department of Neurology, International Medical Center of Japan.
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D002908:Chronic Disease; D003929:Diabetic Neuropathies / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D018384:Oxidative Stress; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D053778:Thiazolidines; D017965:gamma-Linolenic Acid / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D004791:Enzyme Inhibitors; D017127:Glycation End Products, Advanced; D006146:Guanidines; D007328:Insulin; D053778:Thiazolidines; C038131:epalrestat; D017965:gamma-Linolenic Acid; D012236:Rhodanine; D000449:Aldehyde Reductase; C004479:pimagedine